CST3
Cystatin-C
Also known as: CYTC_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P01034
- Gene
- CST3
- Ensembl
- ENSG00000101439
- Chromosome
- 20
- Canonical length
- 146 aa
- Protein class
- Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins
- Subcellular location
- Golgi apparatus,Vesicles
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. The cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes. This gene is located in the cystatin locus and encodes the most abundant extracellular inhibitor of cysteine proteases, which is found in high concentrations in biological fluids and is expressed in virtually all organs of the body. A mutation in this gene has been associated with amyloid angiopathy. Expression of this protein in vascular wall smooth muscle cells is severely reduced in both atherosclerotic and aneurysmal aortic lesions, establishing its role in vascular disease. In addition, this protein has been shown to have an antimicrobial function, inhibiting the replication of herpes simplex virus. Alternative splicing results in multiple transcript variants encoding a single protein. [provided by RefSeq, Nov 2014]
Canonical amino-acid sequenceUniProt
146 residues, UniProt reviewed canonical sequence.
>P01034|CST3
1 MAGPLRAPLL LLAILAVALA VSPAAGSSPG KPPRLVGGPM DASVEEEGVR RALDFAVGEY
61 NKASNDMYHS RALQVVRARK QIVAGVNYFL DVELGRTTCT KTQPNLDNCP FHDQPHLKRK
121 AFCSFQIYAV PWQGTMTLSK STCQDALocalizationUniProt · AlphaFold · HPA
Whether an antibody against CST3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 4,699 nTPM
Expression across tissuesHPA
Tissue
- basal ganglia: 4,699 nTPM
- amygdala: 4,018 nTPM
- choroid plexus: 3,897 nTPM
- cerebral cortex: 2,966 nTPM
- hippocampal formation: 2,915 nTPM
- midbrain: 2,870 nTPM
Single-cell type
- retinal pigment epithelial cells: 11,783 nCPM
- cdc: 11,110 nCPM
- decidual stromal cells: 7,914 nCPM
- epididymal efferent duct absorptive cells: 7,352 nCPM
- esophageal apical cells: 5,196 nCPM
- kupffer cells: 4,973 nCPM
Immune cell
- myeloid DC: 7,978 nTPM
- intermediate monocyte: 6,434 nTPM
- classical monocyte: 4,979 nTPM
- plasmacytoid DC: 4,438 nTPM
- non-classical monocyte: 4,321 nTPM
- total PBMC: 4,253 nTPM
Brain region
- thalamus: 3,248 nTPM
- medulla oblongata: 3,125 nTPM
- midbrain: 2,760 nTPM
- basal ganglia: 2,750 nTPM
- choroid plexus: 2,723 nTPM
- amygdala: 2,627 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CST3.
Disease | AllUniProt
Conditions CST3 is implicated in, by any mechanism.
- Cerebral amyloid angiopathy, CST3-related (CAA-CST3) MIM:105150
- Macular degeneration, age-related, 11 (ARMD11) MIM:611953
- Leukodystrophy, adult-onset, autosomal dominant, without amyloid angiopathy (ADLDWA) MIM:621214
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 73 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Hereditary cerebral amyloid angiopathy, Icelandic type
ReferencesPubMed · IEDB
Publications for CST3 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1 publication
- Isolation and characterization of autoantibodies against human cystatin C.
2016 · Amino Acids · RCR 0.2 · 4 citations
Reference: T cellIEDB
1 publication
- Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides.
2021 · Cell Rep · RCR 0.9 · 19 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.6
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.5
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- defense response
- immune response
- negative regulation of blood vessel remodeling
- negative regulation of extracellular matrix disassembly
- negative regulation of proteolysis
- regulation of tissue remodeling
- supramolecular fiber organization
- negative regulation of collagen catabolic process
- negative regulation of elastin catabolic process
Molecular functions
- amyloid-beta binding
- cysteine-type endopeptidase inhibitor activity
- endopeptidase inhibitor activity
- identical protein binding
- peptidase inhibitor activity
- protease binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CST3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CST3 as an antibody target. Whether an autoantibody or antibody against CST3 could matter depends on whether native CST3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CST3 is annotated as secreted, so native CST3 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label CST3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...